Yes, Lou Gehrig’s disease and ALS (amyotrophic lateral sclerosis) are the same condition. The two names refer to a single progressive disease in which the nerve cells that control voluntary movement gradually break down and die. The medical name has been in use since 1869, while the informal name took hold after New York Yankees first baseman Lou Gehrig was diagnosed at the Mayo Clinic on June 16, 1939, his 36th birthday. Since then, the condition has carried both names interchangeably in the United States.
Why the Disease Has Multiple Names
French neurologist Jean-Martin Charcot first identified and described ALS in 1869, giving it a clinical name that translates roughly to “hardening of the lateral spinal cord with muscle wasting.” That name stuck in medical literature but never caught on with the general public. When Lou Gehrig’s diagnosis forced him to retire from baseball on June 2, 1941, the story made national headlines and gave the disease a human face. Almost overnight, Americans started calling it Lou Gehrig’s disease.
Outside the United States, you may hear a broader umbrella term: motor neuron disease, or MND. In the UK, Australia, and several other countries, MND is the common label. Technically, MND covers a group of related conditions that affect motor neurons, and ALS is the most common type within that group. In American medical practice, ALS and motor neuron disease are often used as near-synonyms because ALS accounts for the vast majority of cases.
What ALS Does to the Body
ALS destroys two types of nerve cells at once. Upper motor neurons run from the brain down through the spinal cord, while lower motor neurons extend from the spinal cord out to the muscles. When both types degenerate, the brain progressively loses the ability to initiate and control movement. Muscles that no longer receive signals weaken, shrink, and eventually stop working.
Researchers still debate where the damage starts. One hypothesis holds that it begins in the brain’s motor cortex and spreads downward, with overactive signaling essentially burning out the lower neurons through a process called excitotoxicity. A competing idea suggests the disease starts at the muscles or the junctions where nerves meet muscle, then works its way back toward the brain. A third possibility is that upper and lower motor neurons degenerate independently. In practice, the result is the same: progressive loss of the ability to walk, speak, swallow, and eventually breathe.
Early Symptoms and How They Vary
ALS does not look the same in everyone. The most common starting point is limb onset, where weakness begins in a hand, arm, or leg. You might notice trouble gripping objects, frequent tripping, or a foot that seems to drag. Roughly two-thirds of people experience this pattern first.
The other major pattern is bulbar onset, which starts with the muscles of the mouth and throat. Early signs include slurred speech, difficulty swallowing, or a voice that sounds unusually nasal or strained. Bulbar onset tends to carry a worse prognosis than limb onset, though the pace of the disease varies widely from person to person. Early symptoms in either type often include muscle stiffness, cramping, and twitching (fasciculations) that can be easy to dismiss as minor complaints.
How ALS Progresses Over Time
ALS generally worsens over time, but progression is not a straight line. Many people experience stretches lasting weeks or months where symptoms stay relatively stable before another period of decline. As the disease advances, weakness and muscle wasting typically spread to other parts of the body, eventually affecting the muscles used for speaking, swallowing, and breathing.
The average survival time after diagnosis is about three years, but that number masks a wide range of outcomes. About 20% of people live five years or more, roughly 10% live beyond ten years, and around 5% survive twenty years or longer. The physicist Stephen Hawking, diagnosed at 21, lived more than 50 years with the disease. There is no single predictable timeline, which is one of the most frustrating aspects for patients and families.
Who Gets ALS
ALS is relatively rare. In the United States, the point prevalence ranges from about 2 to 12 per 100,000 people, and the annual incidence sits between roughly 1 and 2.2 new cases per 100,000. Globally, an estimated 58,000 people are diagnosed each year, and about 331,000 people are living with the disease at any given time.
Most cases, between 90% and 95%, are classified as sporadic, meaning they occur without any known family history. The remaining 5% to 10% are familial, linked to inherited genetic mutations. The most well-known of these involves a gene called SOD1, which became the target of the first gene-specific ALS treatment. Even in sporadic cases, researchers believe a combination of genetic susceptibility and environmental factors likely plays a role, though no single environmental trigger has been definitively identified.
How ALS Is Diagnosed
There is no single blood test or scan that confirms ALS. Diagnosis relies on a clinical framework known as the Gold Coast criteria, which require three things: progressive loss of motor function that was previously normal, evidence that both upper and lower motor neurons are affected, and test results that rule out other conditions that could mimic ALS.
Upper motor neuron damage shows up as abnormally brisk reflexes, muscle spasticity, or slow and poorly coordinated movement. Lower motor neuron damage appears as visible muscle weakness and wasting, or through characteristic patterns on electromyography (EMG), a test that measures the electrical activity in muscles. The diagnostic workup often includes nerve conduction studies, MRI scans, and blood tests, all primarily aimed at eliminating other possibilities such as spinal cord compression, autoimmune conditions, or certain infections. Because of this process-of-elimination approach, diagnosis can take months.
Current Treatment Options
No existing treatment cures ALS, but a few approved medications can slow its progression to varying degrees. The first, approved in 1995, works by reducing levels of a chemical messenger called glutamate that can overstimulate and damage motor neurons. It remains the most widely prescribed ALS drug and modestly extends survival. A second drug, approved in 2017, functions as an antioxidant, potentially reducing the cellular damage caused by oxidative stress in motor neurons.
In 2023, a third treatment was approved specifically for people whose ALS is caused by a mutation in the SOD1 gene. This drug works by dialing down production of the faulty SOD1 protein. It is delivered by injection into the spinal canal and represents the first gene-targeted therapy for any form of ALS. Because SOD1 mutations account for only a small fraction of cases, the drug applies to a limited group of patients, but its approval marked a significant shift toward precision medicine in ALS treatment.
A fourth drug, initially approved in 2022, was voluntarily pulled from the market in 2024 after a larger follow-up trial failed to confirm the benefits seen in earlier, smaller studies. Beyond medication, much of ALS care focuses on maintaining quality of life through physical therapy, speech therapy, nutritional support, and eventually breathing assistance as respiratory muscles weaken.